Abstract 316P
Background
Although Olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer, its effectiveness in patients without BRCA mutations remains under-investigated. This study aims to provide the first evidence on the efficacy of olaparib maintenance therapy in such a context.
Methods
Using real-world data from eleven high-volume tertiary care centers in China, we conducted a retrospective cohort study to assess the efficacy and safety of olaparib maintenance therapy in BRCA wild-type ovarian cancer patients in the first-line setting. Eligible women were identified by medical record review at each institution. The primary objective was the 1-year progression-free survival (PFS) rate. Details of safety profile were also evaluated.
Results
A total of 50 patients with a median age of 54 years were included. Of these patients, 44 (88%) had International Federation of Gynaecology and Obstetrics (FIGO) stage III disease at diagnosis, while 6 (12%) had stage IV disease. The 1-year PFS rate was 75.2% (95% CI, 63.4 to 89.2) and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). All patients received olaparib at a starting dose of 300 mg twice daily and no patients experienced serious adverse events (AEs). Eight (16%) patients had a dose adjustment, but no patients discontinued olaparib treatment due to AEs.
Conclusions
We provide the first evidence that olaparib could be a safe and effective first-line maintenance treatment for women with BRCA wild-type ovarian cancer. These findings propose a new treatment option for this sizable patient subgroup.
Clinical trial identification
NCT05153603.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AZ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract